The U.S. Food and Drug Administration (FDA) approved loncastuximab tesirine-lpyl (ZYNLONTA) to treat adult patients with relapsed or refractory (R/R) large B-cell lymphoma after two or more earlier treatments with systemic therapy including diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma. The FDA approval is based on a Phase 2 study that enrolled 145 patients with R/R DLBCL or high-grade...
Collaborations with Mayo Clinic, Vanderbilt University Medical Center and Weill Cornell Medicine will Increase Representation of Geographically, Ethnically and Economically Underserved Communities in Clinical Trials RYE BROOK, N.Y., May 6, 2021 – The Leukemia & Lymphoma Society (LLS) announced today the launch of the IMPACT (Influential Medicine Providing Access to Clinical Trials) research grants to in...
Background and Purpose Because of the health emergency created by the COVID-19 virus, three COVID-19 vaccinations have been authorized by the U.S. FDA for Emergency Use Administration (EUA). The vaccine clinical trials were streamlined and essentially excluded people with a current or past diagnosis of cancer. Therefore, how people with blood cancer respond to the COVID-19 vaccinations is unknown. The Leukemia ...
RYE BROOK, N.Y., April 22, 2021 /PRNewswire/ -- The Leukemia & Lymphoma Society Therapy Acceleration Program® (LLS TAP) today announced five new investments aimed at speeding the development of new and improved immunotherapies for the treatment of blood cancers. LLS has dedicated more than $100 million over the past several decades, through both grants and TAP investments, to advancing p...
As a leading patient focused organization dedicated to saving lives, we watched in horror the images of George Floyd’s senseless killing last summer and the continued cycle of racial violence and injustice that has followed. We are hopeful that today’s verdict is a first of many steps toward greater justice and equity for Black people and people of color. It is important to acknowledge and recognize th...
Please send all media-related inquiries and interview requests to mediarelations@lls.org.
An LLS representative will respond as soon as possible.